Business
-
Pulmatrix announced that it will halt a Phase 2b trial of PUR1900 dry powder itraconazole (Pulmazole) in patients with allergic bronchopulmonary aspergillosis (ABPA) that was initiated in February 2023. The company says that the move is part… Read more . . .
-
Essential Pharma announced that it has acquired European rights to Teva’s Colobreathe colistimethate sodium inhalation powder from Teva. Colobreathe, which was developed by Forest Laboratories, was approved by the EMA for the treatment of P.… Read more . . .
-
Atai Life Sciences announced that it has invested a total of $50 million to acquire 35.5% of Beckley Psytech, which is developing BPL-003 intranasal synthetic 5-MeO-DMT (mebufotenin). Atai’s subsidiary Innaris Bio is developing a gelling excipient for… Read more . . .
-
According to MannKind Corporation, Sagard Healthcare is paying $150 million and a potential milestone payment of as much as $50 million for a 1% royalty on net sales of Tyvaso treprostinil DPI between October 1, 2023 and December 31, 2042. Tyvaso… Read more . . .
-
Firebrick Pharmaceuticals announced that it has withdrawn its appeal of a decision by the Therapeutic Goods Administration (TGA), which refused to approve the company’s Nasodine povidone-iodine nasal spray as a treatment for the common cold.… Read more . . .
-
According to Liquidia Corporation, the company will immediately take steps toward getting final FDA approval of Yutrepia treprostinil DPI now that the US Court of Appeals has upheld a decision by the Patent Trial and Appeal… Read more . . .
-
Non-profit Harm Reduction Therapeutics (HRT) announced that it has filled the first order for RiVive naloxone nasal spray, which was approved by the FDA in July 2023 as an over-the-counter medication for the treatment of… Read more . . .
-
Vivaldi Biosciences announced that the Flu Lab has provided a grant to fund a transmission study of the company’s DeltaFLU intranasal universal influenza vaccine. According to the company, the study will evaluate the ability of… Read more . . .
-
Marinomed Biotech announced that DKSH subsidiary Favorex has acquired commercialization rights to Marinomed’s Carragelose iota-carrageenan nasal spray for Thailand, Malaysia, Myanmar, and the Philippines. Earlier this year, Carragelose nasal spray was approved in Mexico, where… Read more . . .
-
Lupin announced that the Drug Controller General of India approved the company’s Vilfuro-G vilanterol / fluticasone furoate / glycopyrronium bromide dry powder inhaler for the treatment of COPD, and the company has launched the DPI… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden